QSAM Biosciences Appoints Richard K. Burt, M.D., Pioneer in the Use of Stem Cell Transplants to Treat Autoimmune Diseases, to Scientific Board of Advisors
QSAM Biosciences has appointed Dr. Richard K. Burt to its Scientific Board of Advisors. Dr. Burt is recognized for his expertise in stem cell procedures, vital for the high-dose applications of QSAM's radiopharmaceutical candidate, CycloSam. His experience spans over 35 years in using hematopoietic stem cells for treating autoimmune diseases and conducting NIH-backed clinical trials. The company anticipates that Dr. Burt's guidance will significantly enhance the development and commercialization of CycloSam, which has demonstrated safety and efficacy in both animal studies and a successful human trial.
- Appointment of Dr. Richard K. Burt to the Scientific Board of Advisors is expected to strengthen clinical guidance for CycloSam.
- Dr. Burt's extensive experience and recognition in the field may lead to increased credibility and potential success in clinical development.
- Concerns about continuity and experience gaps in the scientific advisory team without adequate prior members.
- Dependence on a single expert's guidance could pose risks if future alignment or contributions are limited.
Austin, TX, April 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced today that it has appointed Richard K. Burt, M.D., to its Scientific Board of Advisors.
“Stem cell procedures, in which Dr. Burt is a world-renowned expert, are a core safety measure to some of the high dose indications we envision for our lead radiopharmaceutical candidate, CycloSam®, due to the way radiation therapy is delivered to the bone. We also see bone marrow ablation prior to a stem cell transplant, similar to the procedure we performed on a patient last year, and potential future uses to treat sickle cell disease, as key indications for our technology,” stated Douglas R. Baum, the Company’s CEO and Co-Founder. “We believe Dr. Burt will bring invaluable clinical guidance to the development of CycloSam, and we are enthusiastic about the contributions he will make to our long-term success.”
Over the last 35 years, Dr. Burt pioneered the use of hematopoietic stem cells to treat autoimmune diseases and he was among the first doctors in the United States and the World to perform autologous hematopoietic stem cell transplants for numerous immune–mediated diseases including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Crohn’s disease, type 1 diabetes, and other serious conditions. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institute of Health (NIH)
In 2006, Dr. Burt was recognized by Scientific American along with Al Gore and Steve Jobs as one of the top 50 people in the world for improving humanity due to his pioneering stem cell work. In 2011, Science Illustrated recognized Dr. Burt’s stem cell work as one of the top 10 advances of the decade.
About QSAM Biosciences:
QSAM Biosciences, Inc. holds the worldwide license for CycloSam® (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam®, a clinical-staged bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc and subsequently exclusively licensed to QSAM Biosciences, Inc.
CycloSam® has already demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared successful human trial performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat osteosarcoma or other bone metastases. Osteosarcoma is the most common malignant bone tumor among children and adolescents. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation. This drug candidate utilizes an FDA-approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process. Given these factors, management believes there is a strong pathway to commercialization.
CycloSam® is cleared by the FDA under an investigator initiated IND to commence human dosing in patients with osteosarcoma and bone metastasis. CycloSam® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.
Legal Notice Regarding Forward-Looking Statements: This news release contains "Forward-looking Statements". These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, and changes in our business strategies. This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.
Contact
David L. Kugelman
Atlanta Capital Partners LLC
T: (404) 856-9157
dk@atlcp.com
www.atlcp.com
FAQ
What is the significance of Dr. Richard K. Burt's appointment to QSAM?
What is CycloSam, and how does it relate to QSAM Biosciences?
What are the expected benefits of Dr. Burt's expertise for QSAM?
How has CycloSam performed in clinical trials?
What challenges might QSAM face after Dr. Burt's appointment?
